Nichols & Pratt Advisers LLP MA Takes Position in IDEXX Laboratories, Inc. $IDXX

Nichols & Pratt Advisers LLP MA acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,000 shares of the company’s stock, valued at approximately $562,000.

Other hedge funds also recently bought and sold shares of the company. Elyxium Wealth LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth $3,666,459,000. J. Stern & Co. LLP lifted its stake in IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after buying an additional 1,442,174 shares during the period. Wellington Management Group LLP boosted its position in IDEXX Laboratories by 318.1% during the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock valued at $527,162,000 after buying an additional 592,834 shares during the period. Finally, Norges Bank purchased a new stake in IDEXX Laboratories during the fourth quarter valued at about $332,265,000. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of several analyst reports. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. UBS Group reduced their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Citigroup initiated coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 25th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $555.67 on Thursday. The firm has a market capitalization of $43.83 billion, a price-to-earnings ratio of 40.92, a PEG ratio of 3.12 and a beta of 1.55. The stock has a fifty day moving average of $555.09 and a 200 day moving average of $605.73. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm earned $2.91 EPS. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.